Quantinno Capital Management LP Grows Stake in Smith & Nephew plc (NYSE:SNN)

Quantinno Capital Management LP lifted its position in Smith & Nephew plc (NYSE:SNN) by 83.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 97,818 shares of the medical equipment provider’s stock after acquiring an additional 44,592 shares during the period. Quantinno Capital Management LP’s holdings in Smith & Nephew were worth $2,404,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SNN. PNC Financial Services Group Inc. increased its stake in Smith & Nephew by 4.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider’s stock worth $224,000 after acquiring an additional 399 shares during the last quarter. National Bank of Canada FI increased its holdings in Smith & Nephew by 36.5% in the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 446 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in shares of Smith & Nephew by 3.5% in the 4th quarter. Bleakley Financial Group LLC now owns 17,704 shares of the medical equipment provider’s stock valued at $435,000 after acquiring an additional 596 shares during the last quarter. Signaturefd LLC boosted its stake in Smith & Nephew by 4.3% in the fourth quarter. Signaturefd LLC now owns 15,772 shares of the medical equipment provider’s stock valued at $388,000 after acquiring an additional 653 shares in the last quarter. Finally, Principal Securities Inc. lifted its holdings in shares of Smith & Nephew by 87.6% in the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 691 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Hsbc Global Res lowered shares of Smith & Nephew from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. HSBC downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 26th. Canaccord Genuity Group raised their price target on Smith & Nephew from $27.00 to $28.00 and gave the stock a “hold” rating in a report on Thursday, May 1st. Finally, UBS Group cut Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 12th. Six investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.00.

Smith & Nephew Stock Up 1.0%

SNN opened at $29.38 on Wednesday. The business has a 50-day moving average of $27.45 and a two-hundred day moving average of $26.31. Smith & Nephew plc has a 12 month low of $23.69 and a 12 month high of $31.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. The stock has a market capitalization of $12.87 billion, a price-to-earnings ratio of 13.60, a price-to-earnings-growth ratio of 1.26 and a beta of 0.68.

Smith & Nephew Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be paid a $0.447 dividend. The ex-dividend date is Friday, March 28th. This represents a dividend yield of 2.5%. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. Smith & Nephew’s dividend payout ratio (DPR) is 41.20%.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.